Citigroup Boosts Stake in 10x Genomics

Institutional investor increases holdings in biotech firm by over 55%

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Citigroup Inc. has increased its position in 10x Genomics (NASDAQ:TXG) by 55.3% in the third quarter, according to a recent SEC filing. The institutional investor now owns 261,323 shares of the company's stock, worth approximately $3.06 million as of the most recent reporting period.

Why it matters

This move by a major financial institution signals continued confidence in 10x Genomics, a leading provider of advanced genomic analysis solutions. The company's products are widely used in academic, pharmaceutical, and government research, underscoring the growing importance of genomics in scientific discovery and medical innovation.

The details

Citigroup purchased an additional 93,104 shares of 10x Genomics during the third quarter, bringing its total stake in the company to 261,323 shares. This represents about 0.21% of 10x Genomics' outstanding shares. The purchase was part of Citigroup's broader investment strategy, as the bank has also increased its holdings in other biotechnology firms in recent quarters.

  • Citigroup increased its 10x Genomics stake in the 3rd quarter of 2026.

The players

Citigroup Inc.

A major American multinational investment bank and financial services corporation.

10x Genomics

A biotechnology company that specializes in advanced genomic analysis solutions for researchers and scientists.

Got photos? Submit your photos here. ›

The takeaway

Citigroup's increased investment in 10x Genomics underscores the growing importance of genomics research and the company's position as a leader in this field. This move could signal broader institutional confidence in the long-term growth potential of 10x Genomics and the genomics industry as a whole.